HOSPITAL BUDGET IMPACT MODEL OF TV-46000, A LONG-ACTING SUBCUTANEOUS FORMULATION OF RISPERIDONE, VERSUS ONCE-MONTHLY PALIPERIDONE PALMITATE IN ADULTS WITH SCHIZOPHRENIA IN THE UNITED STATES
Author(s)
Jose M. Rubio, MD1, Ayush Patel, MS, PhD2, Mike Philbin, Pharm D, MBA Msc3, Olawemimo Odebiyi, Pharm D3, Arjan J. Postma, MSc4, Hassan T. Elmarkaby, MSc4, Stefan R. Konings, PhD4;
1The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA, 2Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA, 3Teva Branded Pharmaceutical Products R&D, Inc, Parsippany, NJ, USA, 4Asc Academics B.V., Groningen, Netherlands
1The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA, 2Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA, 3Teva Branded Pharmaceutical Products R&D, Inc, Parsippany, NJ, USA, 4Asc Academics B.V., Groningen, Netherlands
OBJECTIVES: Evaluate the financial implications of implementing once-monthly (q1m) TV-46000, a long-acting subcutaneous formulation of risperidone, versus once-monthly paliperidone palmitate (PP1m) for the treatment of schizophrenia from a United States (US) hospital perspective.
METHODS: A hospital budget impact model (HBIM) with time horizons from 1-5 years was developed using a state transition Markov approach. The base case population (n=1000) comprised US adults with a schizophrenia diagnosis eligible for treatment with TV-46000. The base case scenario was a market share split of 0% TV-46000 q1m and 100% PP1m. Sensitivity analysis included testing of different proportions of market shares ranging from 0% to 100% use of TV-46000 q1m. The HBIM used epidemiological inputs, schizophrenia treatment eligibility, payer mix (Medicare, Medicaid, commercial insurance), hospital reimbursement, clinical inputs (eg, relapse rates and hospitalization rates), and included costs (eg, drug acquisition costs). Increased utilization for TV-46000 arose only from PP1m substitution. Inputs on length of stay (LOS) for TV-46000 versus PP1m were derived from the results of a US-based, retrospective, observational cohort study. To estimate hospital costs, the HBIM calculated relapses, relapses resulting in emergency department or inpatient encounters, and LOS for each group.
RESULTS: In the base case scenario of 1000 adult patients treated for schizophrenia, change in utilization mix from 0% TV-46000/100% PP1m to 100% TV-46000/0% PP1m was estimated to reduce total costs by $1,116,108 per 1000 patients ($1116 per patient) over 1 year, and $1,588,777 per 1000 patients ($1589 per patient) over 2 years. For 1000 patients, LOS was reduced by 629.6 days over 1 year and 1531.0 days cumulatively over 2 years; number of relapses (inpatient and emergency department encounters) was reduced by 41.5 and 97.3 over 1 and 2 years, respectively.
CONCLUSIONS: These findings demonstrate the potential economic benefits of TV-46000 versus PP1m for adults with schizophrenia from a US hospital perspective.
METHODS: A hospital budget impact model (HBIM) with time horizons from 1-5 years was developed using a state transition Markov approach. The base case population (n=1000) comprised US adults with a schizophrenia diagnosis eligible for treatment with TV-46000. The base case scenario was a market share split of 0% TV-46000 q1m and 100% PP1m. Sensitivity analysis included testing of different proportions of market shares ranging from 0% to 100% use of TV-46000 q1m. The HBIM used epidemiological inputs, schizophrenia treatment eligibility, payer mix (Medicare, Medicaid, commercial insurance), hospital reimbursement, clinical inputs (eg, relapse rates and hospitalization rates), and included costs (eg, drug acquisition costs). Increased utilization for TV-46000 arose only from PP1m substitution. Inputs on length of stay (LOS) for TV-46000 versus PP1m were derived from the results of a US-based, retrospective, observational cohort study. To estimate hospital costs, the HBIM calculated relapses, relapses resulting in emergency department or inpatient encounters, and LOS for each group.
RESULTS: In the base case scenario of 1000 adult patients treated for schizophrenia, change in utilization mix from 0% TV-46000/100% PP1m to 100% TV-46000/0% PP1m was estimated to reduce total costs by $1,116,108 per 1000 patients ($1116 per patient) over 1 year, and $1,588,777 per 1000 patients ($1589 per patient) over 2 years. For 1000 patients, LOS was reduced by 629.6 days over 1 year and 1531.0 days cumulatively over 2 years; number of relapses (inpatient and emergency department encounters) was reduced by 41.5 and 97.3 over 1 and 2 years, respectively.
CONCLUSIONS: These findings demonstrate the potential economic benefits of TV-46000 versus PP1m for adults with schizophrenia from a US hospital perspective.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE338
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
SDC: Neurological Disorders